Skip to content

Summit Therapeutics

US · SMMT #1207 by market cap Listed 2015
9.95 -0.62 -5.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Summit Therapeutics

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Founded
2003
CEO
Mr. Robert W. Duggan
Employees
265
Headquarters
Miami, Florida, United States of America
Fiscal year end
12-31
Website
smmttx.com

Company profile

Exchange
US
Symbol
SMMT
Market-cap rank
#1207
Listing date
2015-03-05
Market cap
7.96B
Float cap
1.52B
Shares out
799.76M
Float shares
152.29M

Sectors & themes

Biotechnology Top Gainers Yesterday Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.

Summit Therapeutics discussion 0 comments

Add a comment